Redeye comments on Initiator Pharma’s announcement that the last patient has been dosed in the phase IIa proof-of-concept study of pudafensine in vulvodynia. Completing dosing removes the clinical execution risk ahead of the readout. However, topline data are now guided for February 2027 rather than the previous guidance of year-end 2026.
LÄS MER
